ConductScience.org, home
Papers
API referenceFor AI assistants

Paper42200829

Sociodemographic, Clinical, and Therapeutic Characterization of Multiple Myeloma Patients (CharisMMa Study) with Symptomatic Relapse and/or Refractory Disease: An Observational, Multicenter Study in Portugal.

Bergantim R and 12 others. Hematol Rep, 2026. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Sociodemographic, Clinical, and Therapeutic Characterization of Multiple Myeloma Patients (CharisMMa Study) with Symptomatic Relapse and/or Refractory Disease: An Observational, Multicenter Study in Portugal. Papers, record 42200829. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42200829

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Sociodemographic, Clinical, and Therapeutic Characterization of Multiple Myeloma Patients (CharisMMa Study) with Symptomatic Relapse and/or Refractory Disease: An Observational, Multicenter Study in Portugal.
PubMed
Journal
Hematol Rep
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bergantim RRuihttps://orcid.org/0000-0002-7811-9509
2Freitas JGJosé Guilherme
3Gonçalves CCristina
4Martins HHelena
5Marques HHerlanderhttps://orcid.org/0000-0002-5854-4444
6Coelho HHenrique
7Seabra PPatrícia
8Roque AAdrianahttps://orcid.org/0000-0003-4194-9119
9Tavares MMárciohttps://orcid.org/0000-0002-7403-8998
10Pinto PPedro
11Francisco ARAna Rita
12Tato JJoana
13Geraldes CCatarina

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
NATakeda PharmaceuticalsPubMed

Source PubMed

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135,034,310Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany.Adv Ther2022https://conductscience.org/library/papers/35034310PubMed
225,101,266Implications of heterogeneity in multiple myeloma.Biomed Res Int2014https://conductscience.org/library/papers/25101266PubMed
328,582,636Living with the burden of relapse in multiple myeloma from the patient and physician perspective.Leuk Res2017https://conductscience.org/library/papers/28582636PubMed
434,774,462Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.Clin Lymphoma Myeloma Leuk2022https://conductscience.org/library/papers/34774462PubMed
536,980,705Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety.Cancers (Basel)2023https://conductscience.org/library/papers/36980705PubMed
635,768,410Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.Blood Cancer J2022https://conductscience.org/library/papers/35768410PubMed
735,750,956Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis.Pharmacoecon Open2022https://conductscience.org/library/papers/35750956PubMed
831,605,300Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma.Pharmacoecon Open2020https://conductscience.org/library/papers/31605300PubMed
932,391,000Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.Front Immunol2020https://conductscience.org/library/papers/32391000PubMed
1033,549,387Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.Ann Oncol2021https://conductscience.org/library/papers/33549387PubMed
1134,503,130Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.Cancers (Basel)2021https://conductscience.org/library/papers/34503130PubMed
1229,217,780From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.Haematologica2018https://conductscience.org/library/papers/29217780PubMed
1331,859,245Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.Lancet Oncol2020https://conductscience.org/library/papers/31859245PubMed
1438,943,315Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.Am J Hematol2024https://conductscience.org/library/papers/38943315PubMed
1536,891,310CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.Front Immunol2023https://conductscience.org/library/papers/36891310PubMed
1635,662,087Quality of life assessment & out-of-pocket expenditure in multiple myeloma: An observational study.Indian J Med Res2021https://conductscience.org/library/papers/35662087PubMed
1736,658,490Patient perspectives on considerations, tradeoffs, and experiences with multiple myeloma treatment selection: a qualitative descriptive study.BMC Cancer2023https://conductscience.org/library/papers/36658490PubMed
1838,828,933Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.N Engl J Med2024https://conductscience.org/library/papers/38828933PubMed
1927,033,237Treatment of relapsed and refractory multiple myeloma.Haematologica2016https://conductscience.org/library/papers/27033237PubMed
2037,227,998Belantamab mafodotin in multiple myeloma.Expert Opin Biol Ther2023https://conductscience.org/library/papers/37227998PubMed

See all 29 references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42200829

GET https://conductscience.org/api/papers/v1/42200829/references?page=2

API referenceFor AI assistants